The Number of Patients Who Had Baseline PAC ≥ 30.85 ng/dL and/or Baseline ARR ≥ 308.5
| Results in Confirmatory Tests . | Captopril Challenge Test . | Saline Infusion Test . | ||
|---|---|---|---|---|
| . | Positive . | Negative . | Positive . | Negative . |
| Baseline PRA ≤ 0.3 (n) | 1,220 | 86 | 543 | 153 |
| PAC ≥ 30.85, n (%) | 251 (20.6) | 3 (3.5) | 133 (24.5) | 0 (0.0) |
| ARR ≥ 308.5, n (%) | 134 (11.0) | 1 (1.2) | 69 (12.7) | 0 (0.0) |
| Both PAC ≥ 30.85 and ARR ≥ 308.5, n (%) | 134 (11.0) | 1 (1.2) | 69 (12.7) | 0 (0.0) |
| Baseline PRA > 0.3 (n) | 692 | 258 | 410 | 78 |
| PAC ≥ 30.85, n (%) | 162 (23.4) | 29 (11.2) | 83 (20.2) | 2 (2.6) |
| ARR ≥ 308.5, n (%) | 2 (0.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Both PAC ≥ 30.85 and ARR ≥ 308.5, n (%) | 2 (0.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Results in Confirmatory Tests . | Captopril Challenge Test . | Saline Infusion Test . | ||
|---|---|---|---|---|
| . | Positive . | Negative . | Positive . | Negative . |
| Baseline PRA ≤ 0.3 (n) | 1,220 | 86 | 543 | 153 |
| PAC ≥ 30.85, n (%) | 251 (20.6) | 3 (3.5) | 133 (24.5) | 0 (0.0) |
| ARR ≥ 308.5, n (%) | 134 (11.0) | 1 (1.2) | 69 (12.7) | 0 (0.0) |
| Both PAC ≥ 30.85 and ARR ≥ 308.5, n (%) | 134 (11.0) | 1 (1.2) | 69 (12.7) | 0 (0.0) |
| Baseline PRA > 0.3 (n) | 692 | 258 | 410 | 78 |
| PAC ≥ 30.85, n (%) | 162 (23.4) | 29 (11.2) | 83 (20.2) | 2 (2.6) |
| ARR ≥ 308.5, n (%) | 2 (0.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Both PAC ≥ 30.85 and ARR ≥ 308.5, n (%) | 2 (0.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Abbreviations: ARR, aldosterone-to-renin ratio; PAC, plasma aldosterone concentration; PRA, plasma renin activity.
The Number of Patients Who Had Baseline PAC ≥ 30.85 ng/dL and/or Baseline ARR ≥ 308.5
| Results in Confirmatory Tests . | Captopril Challenge Test . | Saline Infusion Test . | ||
|---|---|---|---|---|
| . | Positive . | Negative . | Positive . | Negative . |
| Baseline PRA ≤ 0.3 (n) | 1,220 | 86 | 543 | 153 |
| PAC ≥ 30.85, n (%) | 251 (20.6) | 3 (3.5) | 133 (24.5) | 0 (0.0) |
| ARR ≥ 308.5, n (%) | 134 (11.0) | 1 (1.2) | 69 (12.7) | 0 (0.0) |
| Both PAC ≥ 30.85 and ARR ≥ 308.5, n (%) | 134 (11.0) | 1 (1.2) | 69 (12.7) | 0 (0.0) |
| Baseline PRA > 0.3 (n) | 692 | 258 | 410 | 78 |
| PAC ≥ 30.85, n (%) | 162 (23.4) | 29 (11.2) | 83 (20.2) | 2 (2.6) |
| ARR ≥ 308.5, n (%) | 2 (0.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Both PAC ≥ 30.85 and ARR ≥ 308.5, n (%) | 2 (0.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Results in Confirmatory Tests . | Captopril Challenge Test . | Saline Infusion Test . | ||
|---|---|---|---|---|
| . | Positive . | Negative . | Positive . | Negative . |
| Baseline PRA ≤ 0.3 (n) | 1,220 | 86 | 543 | 153 |
| PAC ≥ 30.85, n (%) | 251 (20.6) | 3 (3.5) | 133 (24.5) | 0 (0.0) |
| ARR ≥ 308.5, n (%) | 134 (11.0) | 1 (1.2) | 69 (12.7) | 0 (0.0) |
| Both PAC ≥ 30.85 and ARR ≥ 308.5, n (%) | 134 (11.0) | 1 (1.2) | 69 (12.7) | 0 (0.0) |
| Baseline PRA > 0.3 (n) | 692 | 258 | 410 | 78 |
| PAC ≥ 30.85, n (%) | 162 (23.4) | 29 (11.2) | 83 (20.2) | 2 (2.6) |
| ARR ≥ 308.5, n (%) | 2 (0.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Both PAC ≥ 30.85 and ARR ≥ 308.5, n (%) | 2 (0.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Abbreviations: ARR, aldosterone-to-renin ratio; PAC, plasma aldosterone concentration; PRA, plasma renin activity.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
